KR20220051365A - 타입 iii 수용체 티로신 키나제 억제제로서 헤테로사이클릭 피라졸 유도체 - Google Patents
타입 iii 수용체 티로신 키나제 억제제로서 헤테로사이클릭 피라졸 유도체 Download PDFInfo
- Publication number
- KR20220051365A KR20220051365A KR1020227009059A KR20227009059A KR20220051365A KR 20220051365 A KR20220051365 A KR 20220051365A KR 1020227009059 A KR1020227009059 A KR 1020227009059A KR 20227009059 A KR20227009059 A KR 20227009059A KR 20220051365 A KR20220051365 A KR 20220051365A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- indazol
- dihydrothieno
- cyclopenta
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891097P | 2019-08-23 | 2019-08-23 | |
| US62/891,097 | 2019-08-23 | ||
| PCT/US2020/047552 WO2021041276A1 (en) | 2019-08-23 | 2020-08-22 | Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220051365A true KR20220051365A (ko) | 2022-04-26 |
Family
ID=74685735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227009059A Pending KR20220051365A (ko) | 2019-08-23 | 2020-08-22 | 타입 iii 수용체 티로신 키나제 억제제로서 헤테로사이클릭 피라졸 유도체 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12448394B2 (https=) |
| EP (1) | EP4017853A4 (https=) |
| JP (1) | JP7651557B2 (https=) |
| KR (1) | KR20220051365A (https=) |
| CN (1) | CN114502553B (https=) |
| AU (1) | AU2020337883B2 (https=) |
| BR (1) | BR112022003383A2 (https=) |
| CA (1) | CA3151821A1 (https=) |
| MX (1) | MX2022002062A (https=) |
| TW (1) | TWI759829B (https=) |
| WO (1) | WO2021041276A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2323952T3 (es) | 2002-05-15 | 2009-07-28 | Janssen Pharmaceutica Nv | 3-aminopirazol triciclicos sustituidos en n como inhibidores receptores de pdfg. |
| RU2425677C2 (ru) | 2005-01-21 | 2011-08-10 | Астекс Терапьютикс Лимитед | Соединения, предназначенные для использования в фармацевтике |
| CN101146532B (zh) | 2005-01-21 | 2012-05-09 | 阿斯泰克斯治疗有限公司 | 药物化合物 |
| JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体 |
| JP2010505859A (ja) | 2006-10-06 | 2010-02-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤およびそれを使用するための方法 |
| KR101122481B1 (ko) | 2007-05-04 | 2012-02-29 | 아이알엠 엘엘씨 | Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 피리미딘 유도체 및 조성물 |
| EA024729B1 (ru) * | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| UA112425C2 (uk) | 2010-12-13 | 2016-09-12 | Еррей Біофарма Інк. | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ |
| US8877763B2 (en) * | 2012-03-22 | 2014-11-04 | Genosco | Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US8853207B2 (en) * | 2012-04-12 | 2014-10-07 | Development Center For Biotechnology | Heterocyclic pyrazole compounds, method for preparing the same and use thereof |
| MX2018006856A (es) | 2015-12-07 | 2018-08-01 | Plexxikon Inc | Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos. |
-
2020
- 2020-08-21 TW TW109128678A patent/TWI759829B/zh active
- 2020-08-22 BR BR112022003383A patent/BR112022003383A2/pt unknown
- 2020-08-22 CN CN202080059010.6A patent/CN114502553B/zh active Active
- 2020-08-22 MX MX2022002062A patent/MX2022002062A/es unknown
- 2020-08-22 EP EP20856905.3A patent/EP4017853A4/en active Pending
- 2020-08-22 KR KR1020227009059A patent/KR20220051365A/ko active Pending
- 2020-08-22 AU AU2020337883A patent/AU2020337883B2/en active Active
- 2020-08-22 WO PCT/US2020/047552 patent/WO2021041276A1/en not_active Ceased
- 2020-08-22 JP JP2022511322A patent/JP7651557B2/ja active Active
- 2020-08-22 US US17/636,116 patent/US12448394B2/en active Active
- 2020-08-22 CA CA3151821A patent/CA3151821A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022545019A (ja) | 2022-10-24 |
| WO2021041276A1 (en) | 2021-03-04 |
| US12448394B2 (en) | 2025-10-21 |
| US20220289759A1 (en) | 2022-09-15 |
| CA3151821A1 (en) | 2021-03-04 |
| AU2020337883B2 (en) | 2025-08-28 |
| EP4017853A4 (en) | 2023-08-30 |
| BR112022003383A2 (pt) | 2022-05-17 |
| CN114502553B (zh) | 2024-07-26 |
| CN114502553A (zh) | 2022-05-13 |
| TW202115087A (zh) | 2021-04-16 |
| JP7651557B2 (ja) | 2025-03-26 |
| TWI759829B (zh) | 2022-04-01 |
| AU2020337883A1 (en) | 2022-03-24 |
| EP4017853A1 (en) | 2022-06-29 |
| MX2022002062A (es) | 2022-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107922431B (zh) | Hpk1抑制剂及其使用方法 | |
| JP2021506864A (ja) | Ｓｏｓ１阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体 | |
| TW202521536A (zh) | Ｃｄｋ抑制劑 | |
| JP2018502853A (ja) | 炎症およびがんを処置するための複素環式ｉｔｋ阻害剤 | |
| TWI648266B (zh) | 作為第iii型受體酪胺酸激酶抑制劑之喹㗁啉化合物 | |
| CN104812756A (zh) | 多激酶通路抑制剂 | |
| JP2021514373A (ja) | Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体 | |
| KR20150027121A (ko) | 신규 화합물 | |
| HUE030773T2 (en) | Nitrogen-containing heterocyclic compounds with inhibitory effect on the production of quinurenine | |
| KR20220085735A (ko) | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 | |
| TW201604188A (zh) | 雜芳族化合物及其作為多巴胺ｄ１配體之用途 | |
| CA2946990A1 (en) | Heterocyclic compounds and their use as dopamine d1 ligands | |
| JP7651557B2 (ja) | Ｉｉｉ型受容体チロシンキナーゼ阻害剤としてのヘテロ環式ピラゾール誘導体 | |
| RU2833004C2 (ru) | Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III | |
| CN114555597A (zh) | 异柠檬酸脱氢酶（idh）抑制剂 | |
| WO2023008577A1 (ja) | Ｒａｓ／Ｒａｆ結合阻害化合物 | |
| HK40012508A (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors | |
| HK40012508B (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |